Benefits
IBS symptom relief — clinical RCT evidence
Multiple double-blind RCTs confirm LactoSpore® significantly reduces IBS symptoms including abdominal pain, bloating, diarrhea, and constipation vs. placebo. A landmark study in 36 IBS patients confirmed significant improvement in overall IBS symptom scores with LactoSpore® supplementation. The spore-forming nature enables consistent, reliable delivery to the intestinal microbiome unlike fragile probiotics.
Superior survival through manufacturing and gastric transit
LactoSpore® endospores are heat-stable up to 80°C and pH-stable across the full gastric acid range (pH 1–3) — enabling inclusion in beverages, baked goods, protein powders, and hot-processed foods where conventional probiotics are destroyed. This stability advantage means the labeled CFU count actually reaches the intestine, unlike many conventional probiotics that lose 90%+ of viable organisms during manufacturing and gastric transit.
Immune system support
Multiple clinical studies confirm LactoSpore® supplementation improves innate immune markers including NK cell activity, secretory IgA production, and macrophage activation. These immune benefits complement the gut microbiome improvements from probiotic colonization, providing comprehensive gut-immune axis support.
Mechanism of action
Spore germination, colonization, and lactic acid microbiome modulation
LactoSpore® B. coagulans endospores pass through the acidic stomach intact, germinating in the neutral pH environment of the small intestine where they produce L(+)-lactic acid. This lactic acid production lowers intestinal pH, creating an environment that inhibits pathogenic bacteria growth while supporting beneficial Lactobacillus and Bifidobacterium species. B. coagulans also produces bacteriocins and antimicrobial peptides that directly suppress Clostridium difficile, E. coli, and other pathogens, while the immune-activating cell wall components (peptidoglycans, lipoteichoic acids) stimulate mucosal immune defense through TLR2/TLR4 signaling.
Clinical trials
Randomized, double-blind, placebo-controlled trial of LactoSpore® (Bacillus coagulans MTCC 5856, 2 billion CFU/day) vs placebo in 36 patients with diarrhea-predominant IBS for 90 days. (Majeed et al. 2018, Nutr J)
36 IBS-D patients. 90-day intervention.
LactoSpore® significantly reduced IBS symptom scores, abdominal pain, bloating, and bowel irregularity vs placebo. Critical caveat: small trial (n=36), industry-funded (Sabinsa); independent peer-reviewed validation modest. Bacillus coagulans is a spore-former — heat-stable, survives gastric acid, longer shelf life than vegetative Lactobacillus. Note: B. coagulans was previously misclassified as Lactobacillus sporogenes — that name persists in older literature but is taxonomically incorrect.